News

Subject to the IND becoming effective, Ignyta plans to initiate a multicenter Phase I/II clinical study of RXDX-101 to be called Study Targeting ALK, ROS1 or TRKA/B/C (STARTRK-1).

Approximately 146 patients have been enrolled in the Phase III study to date. Over the past three months, patient screening by participating hospitals and patient enrollment have steadily

Selinexor (KPT-330), is a first-in-class, oral selective inhibitors of nuclear export (SINE) compound that covalently inhibits exportin-1 (XPO1/CRM1), which leads to the accumulation of tumor suppressor proteins in

The sales and marketing of Khedezla will be supported by Pernix’s team of approximately 90 sales professionals, promoting the product to high desvenlafaxine prescribing physicians. The new drug

The contract was originally awarded in February 2011, with funding of up to $97m over an initial base period ending in February 2014. Novavax and BARDA have agreed

Aires’ lead product candidate, AIR001, is an intermittently nebulized formulation of nitrite that has orphan drug designation in the US and European Union for the treatment of pulmonary

Dihon’s OTC product portfolio includes Kang Wang for the treatment of dandruff and other scalp disorders and Pi Kang Wang, an antifungal cream, as well as TCM product

As part of the deal, Caprion will identify blood-based protein markers for the GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) trial. GLOBAL is a pan-omic study that

The deal includes a licensing fee, milestone payments and royalties based on product sales. The company said that the pharmaceutical partner is dedicated to dermatology with an extensive